SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat: Thursday, September 5 at 10:00 a.m. EDT Cantor Fitzgerald Global Healthcare Conference 2024Fireside chat: Thursday, September 19 at 9:10 a.m. EDT Live and archived webcasts of the fireside chats will be accessible from the company’s website https://ir.structuretx.com/events-presentations/events. Replays of the webcasts will be available for 90 days. About Structure TherapeuticsStructure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com. Investors:Danielle KeatleyStructure Therapeutics Inc.ir@structuretx.com Media:Dan Budwick1ABDan@1abmedia.com